MX2020012137A - Inhibidores de mcl-1. - Google Patents
Inhibidores de mcl-1.Info
- Publication number
- MX2020012137A MX2020012137A MX2020012137A MX2020012137A MX2020012137A MX 2020012137 A MX2020012137 A MX 2020012137A MX 2020012137 A MX2020012137 A MX 2020012137A MX 2020012137 A MX2020012137 A MX 2020012137A MX 2020012137 A MX2020012137 A MX 2020012137A
- Authority
- MX
- Mexico
- Prior art keywords
- mcl
- inhibitors
- compounds
- methods
- present disclosure
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D267/20—[b, f]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
- C07C381/10—Compounds containing sulfur atoms doubly-bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Abstract
La presente descripción se refiere en general a compuestos y composiciones farmacéuticas que se pueden utilizar en métodos para tratar el cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671306P | 2018-05-14 | 2018-05-14 | |
| US201862749918P | 2018-10-24 | 2018-10-24 | |
| PCT/US2019/032053 WO2019222112A1 (en) | 2018-05-14 | 2019-05-13 | Mcl-1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012137A true MX2020012137A (es) | 2021-01-29 |
Family
ID=66770559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012137A MX2020012137A (es) | 2018-05-14 | 2019-05-13 | Inhibidores de mcl-1. |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US10703733B2 (es) |
| EP (2) | EP3793565B1 (es) |
| JP (3) | JP6899975B2 (es) |
| KR (2) | KR102551319B1 (es) |
| CN (2) | CN112118845B (es) |
| AU (3) | AU2019269391B2 (es) |
| BR (1) | BR112020021648A2 (es) |
| CA (1) | CA3099152C (es) |
| CL (1) | CL2020002919A1 (es) |
| CO (1) | CO2020014009A2 (es) |
| CR (1) | CR20200544A (es) |
| CY (1) | CY1125065T1 (es) |
| DK (1) | DK3793565T3 (es) |
| ES (1) | ES2907923T3 (es) |
| HR (1) | HRP20220215T1 (es) |
| HU (1) | HUE057852T2 (es) |
| IL (2) | IL291430B2 (es) |
| LT (1) | LT3793565T (es) |
| MX (1) | MX2020012137A (es) |
| PE (1) | PE20210004A1 (es) |
| PH (1) | PH12020551881A1 (es) |
| PL (1) | PL3793565T3 (es) |
| PT (1) | PT3793565T (es) |
| SG (1) | SG11202010964VA (es) |
| SI (1) | SI3793565T1 (es) |
| TW (2) | TWI719478B (es) |
| UA (1) | UA125163C2 (es) |
| WO (1) | WO2019222112A1 (es) |
| ZA (1) | ZA202007007B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3793565B1 (en) | 2018-05-14 | 2022-01-05 | Gilead Sciences, Inc. | Mcl-1 inhibitors |
| WO2021005043A1 (en) | 2019-07-09 | 2021-01-14 | Janssen Pharmaceutica Nv | Macrocyclic spirocycle derivatives as mcl-1 inhibitors |
| EP4045083B1 (en) | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| CN114787139A (zh) | 2019-11-26 | 2022-07-22 | 吉利德科学公司 | 用于制备mcl1抑制剂的方法和中间体 |
| JP2023509881A (ja) | 2019-12-24 | 2023-03-10 | カルナバイオサイエンス株式会社 | ジアシルグリセロールキナーゼ調節化合物 |
| WO2021211922A1 (en) * | 2020-04-16 | 2021-10-21 | Prelude Therapeutics, Incorporated | Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein |
| WO2021250102A1 (en) | 2020-06-10 | 2021-12-16 | Janssen Pharmaceutica Nv | Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1 |
| AU2021381769A1 (en) | 2020-11-19 | 2023-06-22 | Gilead Sciences, Inc. | Processes and intermediates for preparing macrocyclic mcl1 inhibitors |
| WO2022129331A1 (en) | 2020-12-17 | 2022-06-23 | Janssen Pharmaceutica Nv | Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| EP4330262A1 (en) | 2021-04-26 | 2024-03-06 | JANSSEN Pharmaceutica NV | Macrocyclic 2-allyltetrahydrofurans as inhibitors of mcl-1 |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| KR20240019330A (ko) | 2021-06-11 | 2024-02-14 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 저해제와 항체 약물 접합체의 조합 |
| TW202315637A (zh) | 2021-06-11 | 2023-04-16 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| WO2023088894A1 (en) | 2021-11-16 | 2023-05-25 | Janssen Pharmaceutica Nv | Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1 |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| TW202400610A (zh) | 2022-05-04 | 2024-01-01 | 美商基利科學股份有限公司 | 某些ｍｃｌ－１抑制劑之鹽及同質多形體 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| PL3153514T3 (pl) | 2004-05-13 | 2022-01-10 | Icos Corporation | Chinazolinony jako inhibitory ludzkiej 3-kinazy fosfatydyloinozytolowej delta |
| US20090142345A1 (en) | 2005-03-15 | 2009-06-04 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for cancer |
| CA2607147C (en) | 2005-05-09 | 2018-07-17 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| JP5252635B2 (ja) | 2005-07-01 | 2013-07-31 | メダレックス インコーポレーティッド | プログラム死リガンド１（ｐｄ−ｌ１）に対するヒトモノクローナル抗体 |
| KR101737753B1 (ko) | 2007-03-12 | 2017-05-18 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| HUE025283T2 (en) | 2007-08-02 | 2016-03-29 | Gilead Biologics Inc | LOX and LOX2 inhibitors and their use |
| PL2310509T3 (pl) | 2008-07-21 | 2015-08-31 | Apogenix Ag | Jednołańcuchowe cząsteczki TNFSF |
| US8652843B2 (en) | 2008-08-12 | 2014-02-18 | Oncomed Pharmaceuticals, Inc. | DDR1-binding agents and methods of use thereof |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| TWI491606B (zh) | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| KR20130008021A (ko) | 2010-02-04 | 2013-01-21 | 길리아드 바이오로직스, 인크. | 리실 산화효소-유사 2 (ｌｏｘｌ2)에 결합하는 항체, 및 그를 위한 사용 방법 |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| PT2608809T (pt) | 2010-08-27 | 2019-08-26 | Gilead Biologics Inc | Anticorpos para a metaloproteinase 9 da matriz |
| JP5947311B2 (ja) | 2010-12-09 | 2016-07-06 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するためのキメラ抗原受容体改変ｔ細胞の使用 |
| TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
| JP6101205B2 (ja) | 2011-08-23 | 2017-03-22 | 中外製薬株式会社 | 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体 |
| GB201115529D0 (en) | 2011-09-08 | 2011-10-26 | Imp Innovations Ltd | Antibodies, uses and methods |
| WO2013052699A2 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| WO2013116562A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Calistoga Llc | Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile |
| TW201427995A (zh) | 2012-09-24 | 2014-07-16 | Gilead Sciences Inc | 抗ｄｄｒ１抗體 |
| AU2013364068B2 (en) | 2012-12-21 | 2016-10-20 | Gilead Calistoga Llc | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors |
| US9029384B2 (en) | 2012-12-21 | 2015-05-12 | Gilead Calistoga, LLC. | Phosphatidylinositol 3-kinase inhibitors |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| KR101709436B1 (ko) | 2013-06-14 | 2017-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 포스파티딜이노시톨 3-키나제 억제제 |
| US9657023B2 (en) | 2013-07-30 | 2017-05-23 | Gilead Connecticut, Inc. | Polymorph of Syk inhibitors |
| TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| EP3122353B1 (en) * | 2014-03-27 | 2020-10-28 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| US10865242B2 (en) | 2014-04-10 | 2020-12-15 | Seattle Children's Hospital | Method and compositions for cellular immunotherapy |
| TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對ｃｄ１９具專一性之抗體及嵌合抗原受體 |
| JO3474B1 (ar) * | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| EA201790395A1 (ru) | 2014-09-26 | 2017-08-31 | Джилид Сайэнс, Инк. | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы |
| MX2017007138A (es) | 2014-12-03 | 2017-08-28 | Juno Therapeutics Inc | Metodos y composiciones para terapia celular adoptiva. |
| WO2016100236A2 (en) | 2014-12-15 | 2016-06-23 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
| CA2985642A1 (en) | 2015-05-15 | 2016-11-24 | Gilead Sciences, Inc. | Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase |
| US20180161368A1 (en) | 2015-05-29 | 2018-06-14 | Juno Therapeutics, Inc. | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
| BR112018005295A2 (pt) | 2015-09-17 | 2018-12-11 | Novartis Ag | terapias com célula t car com eficácia aumentada |
| WO2017147410A1 (en) | 2016-02-25 | 2017-08-31 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| MA49908A (fr) | 2017-08-18 | 2021-04-28 | Amgen Inc | Composés inhibant la protéine mcl-1 |
| US11279712B2 (en) | 2017-08-29 | 2022-03-22 | Amgen Inc. | Macrocyclic compounds that inhibit MCL-1 protein |
| MA50413A (fr) | 2017-10-19 | 2020-08-26 | Amgen Inc | Dérivés de benzimidazole et leurs utilisations |
| EP3762393B1 (en) | 2018-03-05 | 2023-01-11 | Amgen Inc. | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere mcl-1 protein antagonists |
| EP3793565B1 (en) | 2018-05-14 | 2022-01-05 | Gilead Sciences, Inc. | Mcl-1 inhibitors |
| AU2019271126A1 (en) | 2018-05-14 | 2020-12-10 | Reata Pharmaceuticals, Inc. | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway |
| JP2021523200A (ja) | 2018-05-15 | 2021-09-02 | ルンドベック ラ ホーヤ リサーチ センター，インク． | Ｍａｇｌ阻害剤 |
| EP3826999A1 (en) | 2018-07-24 | 2021-06-02 | Epizyme Inc | Pyridin-2-one compounds useful as smarca2 antagonists |
| CN113166173A (zh) | 2018-11-09 | 2021-07-23 | 普莱鲁德疗法有限公司 | 作为骨髓细胞白血病1(mcl-1)蛋白抑制剂的螺-磺酰胺衍生物 |
| US11498928B2 (en) | 2019-01-18 | 2022-11-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic spiroethers as Mcl-1 inhibitors |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| CN114787139A (zh) | 2019-11-26 | 2022-07-22 | 吉利德科学公司 | 用于制备mcl1抑制剂的方法和中间体 |
| JP2021161114A (ja) | 2020-03-31 | 2021-10-11 | アムジエン・インコーポレーテツド | Ｍｃｌ−１化合物のメチル化 |
| TWI827924B (zh) | 2020-05-06 | 2024-01-01 | 美商安進公司 | 大環Mcl-1抑制劑中間體的閉環合成 |
| US20230174496A1 (en) | 2020-05-06 | 2023-06-08 | Amgen Inc. | Synthesis of Vinylic Protected Alcohol Intermediates |
| WO2021250102A1 (en) | 2020-06-10 | 2021-12-16 | Janssen Pharmaceutica Nv | Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1 |
| JP2023532592A (ja) | 2020-07-08 | 2023-07-28 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１の阻害剤としての大環状エーテル含有インドール誘導体 |
| AU2021381769A1 (en) | 2020-11-19 | 2023-06-22 | Gilead Sciences, Inc. | Processes and intermediates for preparing macrocyclic mcl1 inhibitors |
-
2019
- 2019-05-13 EP EP19728793.1A patent/EP3793565B1/en active Active
- 2019-05-13 LT LTEPPCT/US2019/032053T patent/LT3793565T/lt unknown
- 2019-05-13 HR HRP20220215TT patent/HRP20220215T1/hr unknown
- 2019-05-13 CA CA3099152A patent/CA3099152C/en active Active
- 2019-05-13 PL PL19728793T patent/PL3793565T3/pl unknown
- 2019-05-13 KR KR1020207035485A patent/KR102551319B1/ko active IP Right Grant
- 2019-05-13 SG SG11202010964VA patent/SG11202010964VA/en unknown
- 2019-05-13 DK DK19728793.1T patent/DK3793565T3/da active
- 2019-05-13 AU AU2019269391A patent/AU2019269391B2/en active Active
- 2019-05-13 US US16/410,457 patent/US10703733B2/en active Active
- 2019-05-13 ES ES19728793T patent/ES2907923T3/es active Active
- 2019-05-13 UA UAA202006695A patent/UA125163C2/uk unknown
- 2019-05-13 IL IL291430A patent/IL291430B2/en unknown
- 2019-05-13 JP JP2020564228A patent/JP6899975B2/ja active Active
- 2019-05-13 CN CN201980032695.2A patent/CN112118845B/zh active Active
- 2019-05-13 HU HUE19728793A patent/HUE057852T2/hu unknown
- 2019-05-13 SI SI201930181T patent/SI3793565T1/sl unknown
- 2019-05-13 CR CR20200544A patent/CR20200544A/es unknown
- 2019-05-13 EP EP21218221.6A patent/EP4029868A1/en active Pending
- 2019-05-13 MX MX2020012137A patent/MX2020012137A/es unknown
- 2019-05-13 BR BR112020021648-8A patent/BR112020021648A2/pt unknown
- 2019-05-13 PE PE2020001829A patent/PE20210004A1/es unknown
- 2019-05-13 KR KR1020237022152A patent/KR20230107889A/ko active IP Right Grant
- 2019-05-13 WO PCT/US2019/032053 patent/WO2019222112A1/en unknown
- 2019-05-13 CN CN202310897123.9A patent/CN117304130A/zh active Pending
- 2019-05-13 PT PT197287931T patent/PT3793565T/pt unknown
- 2019-05-14 TW TW108116508A patent/TWI719478B/zh active
- 2019-05-14 TW TW110107128A patent/TWI813957B/zh active
-
2020
- 2020-04-23 US US16/857,021 patent/US10988451B2/en active Active
- 2020-10-27 IL IL278336A patent/IL278336B/en unknown
- 2020-11-03 PH PH12020551881A patent/PH12020551881A1/en unknown
- 2020-11-10 CL CL2020002919A patent/CL2020002919A1/es unknown
- 2020-11-10 CO CONC2020/0014009A patent/CO2020014009A2/es unknown
- 2020-11-10 ZA ZA2020/07007A patent/ZA202007007B/en unknown
-
2021
- 2021-02-09 US US17/171,201 patent/US11643400B2/en active Active
- 2021-03-09 JP JP2021037000A patent/JP7240431B2/ja active Active
- 2021-05-25 AU AU2021203373A patent/AU2021203373B2/en active Active
-
2022
- 2022-03-16 CY CY20221100208T patent/CY1125065T1/el unknown
-
2023
- 2023-03-03 JP JP2023032872A patent/JP2023060145A/ja active Pending
- 2023-03-09 US US18/181,336 patent/US20230312490A1/en active Pending
- 2023-11-24 AU AU2023270332A patent/AU2023270332A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202007007B (en) | Mcl-1 inhibitors | |
| PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
| PH12020550622A1 (en) | Kras g12c inhibitors | |
| MX2018005600A (es) | Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello. | |
| PH12020550857A1 (en) | Polycyclic compounds as allosteric shp2 inhibitors | |
| MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| CR20190478A (es) | Inhibidores de pd-1/pd-l1 | |
| MX2018013983A (es) | Inhibidores g12c de kras. | |
| MX2022007472A (es) | Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario. | |
| MX2019007243A (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
| EP4252851A3 (en) | Ezh2 inhibitors for treating lymphoma | |
| PH12019502049A1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| PH12020552214A1 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| MX2019001011A (es) | Compuestos farmaceuticos. | |
| MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
| MX2018001756A (es) | Benzimidazoles sustituidos, su preparacion y su uso como productos farmaceuticos. | |
| MX2017011018A (es) | Inhibicion de la actividad de olig2. | |
| EA031679B9 (ru) | Производные тетрагидрохинолина в качестве ингибиторов бромодомена | |
| ZA201901367B (en) | Inhibition of olig2 activity | |
| MX2018005004A (es) | Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos. | |
| PH12016501838A1 (en) | Compounds and their methods of use | |
| MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. | |
| MX2020010156A (es) | Inhibidores de la secrecion de proteina cdp. | |
| TW202417457A (zh) | Mcl-1抑制劑 | |
| EA202092239A1 (ru) | Ингибиторы mcl-1 |